Northwest Biotherapeutics (OTC: NWBO)
Northwest Biotherapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Northwest Biotherapeutics Company Info
Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.
News & Analysis
Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?
In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.
Did Northwest Biotherapeutics Just Check Off 1 Box Needed for Its Stock to Double?
Will a 14-year clinical trial evaluating an immunotherapy for the most lethal form of brain cancer have a positive outcome?
Why Northwest Biotherapeutics, Accuray, and U.S. Steel Slumped Today
Even though the market kept climbing Wednesday, these three stocks couldn't keep up. Find out why.
5 Stocks We're Staying Away From in 2016
If you want to do well in the markets, it helps to know which stocks you shouldn't buy.
3 Stocks I Would Avoid at All Costs
If you want to beat the market, start by knowing which stocks you shouldn't buy.
Why Shares of Northwest Biotherapeutics Inc Are Crashing Today
News of a phase 3 trial halt for the company's lead compound DCVax-L send investors running.
2 Biotech Stocks Wall Street Hates
MannKind and Northwest Biotherapeutics have attracted ginormous short positions this year. Is the Street wrong about these stocks?
This Illegal Drug Could Be the Answer to Fighting Brain Cancer
Could this illegal drug unlock the secret to fighting brain cancer? A recently released study by a group of London researchers would suggest so.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.